Dialysis industry news

Stories from the dialysis comunity across the globe.



Company Shares of NxStage Medical, Inc. Rally 1.68% - American Trade Journal PDF Print

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) appreciated by 1.68% during the past week but lost 6.88% on a 4-week basis. The shares have outperformed the S&P 500 by 1.69% in the past week but underperformed the index by 6.09% in the last 4 weeks.

For the current week, the company shares have a recommendation consensus of Buy. Nxstage Medical, Inc. has dropped 22.14% during the last 3-month period . Year-to-Date the stock performance stands at -19.19%. The company shares have rallied 6.15% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $15.36 and the 200 day moving average is recorded at $17.18. S&P 500 has rallied 5.03% during the last 52-weeks. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $14.24 and hit $14.56 on the upside , eventually ending the session at $14.49, with a gain of 2.48% or 0.35 points. The heightened volatility saw the trading volume jump to 380,210 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $916 million. The 52-week low of the share price is at $11.5 . On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The (President), of Nxstage Medical, Inc., Turk Joseph E Jr had unloaded 2,000 shares at $15.36 per share in a transaction on June 23, 2015. The total value of transaction was $30,720. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...

 
Prior Pelvic Irradiation Does Not Predict Cystectomy Outcomes - Renal and Urology News PDF Print
July 13, 2015 Prior Pelvic Irradiation Does Not Predict Cystectomy Outcomes - Renal and Urology News
Bladder cancer patients with and without a history of pelvic irradiation have similar recurrence-free and cancer-specific survival rates.

Prior pelvic irradiation does not increase bladder cancer patients' risk of disease recurrence or death from the malignancy following radical cystectomy, according to a new study.  

Bladder cancer patients with a history of pelvic irradiation, however, to present with more advanced disease.

Daniel P. Nguyen, MD, of Weill Cornell Medical College-New York Presbyterian Hospital in New York, and colleagues studied 364 patients who underwent radical cystectomy for bladder cancer from July 2001 to September 2013. Of these, 37 (10%) had a history of pelvic irradiation and 327 (90%) did not. The prior irradiation group had a significantly higher proportion of T4 disease than the non-irradiated patients (35% vs. 11%). 

At 3 years, the irradiated and non-irradiated patients had estimated bladder cancer recurrence-free survival rates of 70% and 77%, respectively, and estimated bladder cancer-specific survival rates of 64% and 69%, respectively, Dr. Nguyen's group reported online ahead of print in Urology. None of these between-group differences were statistically significant. In multivariate analysis, a history of pelvic irradiation did not predict bladder cancer recurrence or bladder cancer-specific death. The rates of diversion-related complications between the groups also were not statistically significant.

The researchers noted that pelvic lymph node dissection could not be performed in 7 of the 37 patients with a history of pelvic irradiation.

The indications for prior pelvic irradiation included prostate cancer (30 patients), gynecologic cancer (4 patients), colorectal cancer (2 patients), and testicular seminoma (1 patient).

The authors pointed out that their study was limited to bladder cancer patients who underwent radical cystectomy, so their results cannot be generalized to all patients with a history pelvic irradiation who later develop bladder cancer. Additionally, the study population included a relatively small number of patients with a history of pelvic irradiation.

...

 
Parking swipe cards for dialysis patients - The Maitland Mercury PDF Print
Rutherford gets new rescue paramedic

After a tough six weeks of simulated swift water rescues, cliff rescues, motor vehicle collisions and building collapses, ...

...

 
New surgical method preserves long-term renal function following removal of ... - News-Medical.net PDF Print

Renal cell carcinomas are one of the most common types of cancer. In order to preserve its wide range of functions, every effort is made not to remove the entire kidney, but rather just a portion of it. A surgical method that preserves long-term renal function has now been carried out successfully for the first time in the Department of Urology at the MedUni Vienna and Vienna General Hospital.

A surgical ultrasound device is used that was previously used for liver cell carcinomas. In the pilot study, recently published in the highly respected journal "World Journal of Urology", this method has now been applied successfully at the Department of Urology at the Medical University of Vienna for the first time to the surgical treatment of complex renal tumours.

Patients benefit twice from the new technique: during the operation itself, the risk of bleeding and complications is lower. In the long term, renal function is preserved and there are no long-term consequences of renal impairment.

Until now, "cold ischaemia" has been used during the removal of renal tumours. With this method, the blood vessels supplying the kidney are clamped and the kidney is cooled. This is essential since the kidney bleeds very heavily when incised - and in humans, around 15 to 20 per cent of the entire blood supply is located in the two kidneys. "Cold ischaemia", however, has a serious disadvantage: the clamping of the vessels damages the renal vessels, significantly increasing the long-term risk of renal impairment.

Solution for a major surgical problem

This does not happen in procedures using the CUSA (Cavitron Ultrasonic Surgical Aspirator) ultrasound device, as study leader Shahrokh Shariat, Head of the  University Department of Urology at the MedUni Vienna and Vienna General Hospital, explains: "With the CUSA ultrasound device, the kidney continues to be perfused with blood during the surgical procedure. As our study shows, the new surgical technique allows renal function to be fully maintained, even though we can achieve the same oncological and surgical results as we do with clamping the organ. This has enabled us to resolve one of the major surgical problems of the last two decades."

Important renal functions remain intact

The problem of clamping and associated long-term damage only became apparent with the advances achieved in imaging with ultrasound and computed tomography. As a result of these advances, around 80 per cent of renal tumours are now detected so early that kidney-sparing treatment is possible without removal of the entire organ. The preservation of ideally both kidneys is important because the kidney performs a range of vital functions which diminish with age and as a result of kidney-damaging conditions such as diabetes and high blood pressure.

http://www.meduniwien.ac.at/

...

 
World Market Report for Dialysis Equipment and Services 2015 with Forecasts to ... - Virtual-Strategy Magazine (press release) (registration) (blog) PDF Print
image

Dublin, July 13, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/bhvbgz/the_world_market) has announced the addition of the "The World Market for Dialysis Equipment and Services (United States, Japan, UK, Germany, France, Italy, India, China, Australia, Canada, Brazil, Mexico, South Africa, Russia and Other Nations)" report to their offering.

The dialysis industry enjoys a unique place in the healthcare sector with a comparatively small patient base but large revenue base for needed services. The industry encompasses the medical device industry (dialysis products and supplies segment) and the healthcare services industry (dialysis services segment). The stable customer base also explains how the dialysis industry is noncyclical in nature and is only minimally affected by the vagaries of economic downturns. This report looks at both the equipment and service aspects of the dialysis industry. The industry enjoys a unique place in the healthcare sector. The industry encompasses two very lucrative segments -- the medical device industry (dialysis products and supplies segment) and the healthcare services industry (dialysis services segment).

The dialysis industry remains a robust, multi-billion dollar business that has managed to fuel its growth engine in the past 5 years. What makes this market more interesting and challenging is its relatively small customer base - a bit under two million dialysis patients form its entire universe. It is the high value of these customers that make this a competitive industry. There are several key issues and trends impacting the future of the dialysis market. Demographics, insurance and reimbursement issues, and consolidation in the industry will continue to influence the outcome of the market in the future.

The report includes:

  • Key Data and Analysis in this report includes:
  • Detailed Forecasts to 2017
  • In-Depth Profiles of the Competitive Companies in Dialysis Treatment, Equipment and Supplies.
  • Scores of Figures and Tables featuring useful data, demographic and market trends that can be used to supplement internal memos or presentation.
  • Detailed World Dialysis Market Review including specific reviews of the dialysis service, equipment and supplies market in the United States, Japan, UK, Italy, India, China and Australia and Canada.
  • Market Share of Major Care and Equipment Providers.
  • The Changing Regulatory Environment.
  • Detailed Patient Demographics Current Data, Forecasts and Trends.

Issues and trends explored in this study include:

  • Innovation Pathway at FDA
  • Dialyzers
  • Prismaflex System Software
  • Wearable Artificial Kidney
  • Implantable Artificial Kidney
  • Prevalence of Diabetes in Developing Regions
  • Insurance and Reimbursement Issues
  • Access to Care for Native Populations
  • Kidney Transplantation
  • Product Development and Innovation
  • Consolidation and Joint Ventures in the Industry
  • Home Dialysis
  • Heat Disinfection for Water Quality
  • Dialysis Treatment Comfort

Companies Featured:

(C) Copyright 2015 GlobeNewswire, Inc. All rights reserved.

...

 
<< Start < Prev 101 102 103 104 105 106 107 108 109 110 Next > End >>

Page 102 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.